List of Artificial Intelligence Companies in California - 253

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

AcelaBio, wholly owned by The Alimentiv Health Trust, was incorporated in 2020 and aims to meet the growing clinical research demand for quality and efficiency in laboratory service. Our state-of-the-art facility, located in San Diego, California, is built on deep expertise in clinical and precision medicine research and our scientific and operational experts are dedicated to delivering reliable, high-quality data.

Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinson's, diabetes and cancer. Acelot's platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases. We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS. Our platform was invented by UCSB Computer Science Professor Dr. Ambuj Singh. Acelot's first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimer's. ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a robust discovery pipeline.

AcuraStem (acurastem.com) is a near-to-clinic, patient-based, drug development company pioneering drug discovery and ultimately how treatments are developed for neurodegenerative diseases—including sporadic ALS and FTD. Enabled by our ground-breaking iNeuroRx® technology platform - AcuraStem has discovered and is now advancing drug candidates that promise to strongly impact disease progression for most patients, including those for whom the genetic cause of their disease is unknown (i.e. sporadic ALS and FTD patients). The causes of neurodegenerative diseases are complex, and genetically defined forms of disease (e.g. C9ORF72-ALS and FTD) only account for a small percentage of cases. Thus, many scientists didn’t believe it was possible to develop a single effective treatment that could work broadly for all patients. But AcuraStem has shown with its extremely promising therapeutic programs for ALS and FTD that it can be done.

Aether's mission is to build a future of abundance for the human race. We believe that the machinery of nature can be reverse engineered to manufacture any arrangement of atoms desired, enabling the production of new products anywhere on earth.

Afecta Pharmaceuticals is an early clinical stage small molecule therapeutics company focused on developing precision medicines to treat chronic disorders and cancers more effectively. Afecta has a validated, proprietary Artificial Intelligence disease/drug targeting platform, PharmetRx®, to discover and optimize Multi-Target drug compounds and formulate them in NanoRx®, our tissue-specific drug delivery technology. Backed by an experienced management team, Afecta is currently advancing AFX-220, our clinically proven lead candidate that effectively treats the disruptive behaviors that occur in children and adolescents with several neurodevelopmental disorders such as Autism, AD/HD, and others. Please visit our website to learn more, register to access our Executive Summary, and receive our latest updates.

Ainnocence is a next-generation biotech company with a fast, self-evolving AI drug design platform. The company's third-generation AI system delivers lightning-fast virtual screening and multi-objective pharmacological profile optimization for small-molecule, antibody, and other complex therapeutic modalities. This platform provides a computational screening capacity of up to 10^10 protein sequences or chemical compounds within hours. The end results are a shortlist of candidates with a very high wet-lab hit rate, and a dramatically reduced discovery time and cost. To learn more, visit ainnocence.com.

Ainos Inc. is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, women's health, pneumonia, Ainos Pen, AI Nose, and other medical technologies. The company was founded in 1984 and is engaged in developing innovative medical technologies for point-of-care testing and safe and effective treatments for various health conditions.

We are creating a new category of medicines with the application of spatial biology and AI.

Improve yield, reduce deviations, and ensure product quality in GxP pharmaceutical manufacturing with real-time, practical Artificial Intelligence (AI)- powered software as a service solutions.

Building a modern operating system for IVF, powered by artificial intelligence.

AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third-party providers to manage their patients' and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving ISO 27001 Certification, SOC 2 Type 2 Certification and HIPAA compliance attestation. AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers. For more information, visit alivecor.com.

ATEC is a medical device company dedicated to revolutionizing the approach to spine surgery through innovation. ATEC’s Organic Innovation Machine™ is the greatest concentration of spine knowhow in the industry and committed to the creation of clinical distinction. Leveraging 100% spine focus and expertise, we seek to improve spine surgery by rethinking, redesigning and seamlessly integrating the technologies required from the ground up. The innovation that results from that process is being rapidly adopted because, like us, spine surgeons covet informatic and procedural sophistication that enables more predictable, more reproducible care. Our flagship technology, the Prone TransPsoas (PTPTM) Procedure, leveraged decades of experience to advance first-generation lateral surgery with a more familiar patient position and elevated neuromonitoring.   EOS imaging, the backbone of ATEC’s informatic ecosystem, provides radiographic imaging, enabling standing, full-body, global alignment assessments. We are further developing EOS technology to elevate spine care with unprecedented capabilities. Our vision is to be the standard bearer in spine. Visit our website for more information: www.atecspine.com

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop

Aluna is designed to help you understand your chronic respiratory condition (such as asthma) and allow you to take control of your lung health. Using a combination of machine learning, our spirometer device and mobile app, you can now use the daily measurements to help you understand and manage your asthma.

Focusing on generating innovative biological respondents with a unique mode of action coupled with conditionally activated characteristics, we handle high-value disease targets with huge upside potential, which are otherwise intractable for traditional targeting approaches.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Anivive is focused on reshaping pet healthcare by bringing together experts in software development, veterinary medicine, and clinical research to accelerate the development of novel therapeutics. Anivive. Smarter for pet health.

Applied Surgical Robotics is a MedTech company focused on developing robotic technology and SaaS software solutions to improve surgical precision.

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

Ardigen is a bioinformatics company that specializes in AI-driven solutions for drug discovery and precision medicine.

ArsenalBiosciences, Inc., is a privately held, clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.

Artera is a SaaS digital health leader redefining patient communications. Artera is trusted by 700+ healthcare systems and federal agencies to facilitate approximately 2.2 billion messages annually, reaching 100+ million patients. The Artera platform integrates across a healthcare organization’s tech stack, EHRs and third-party vendors to unify, simplify and orchestrate digital communications into the patient’s preferred channel (texting, email, IVR, and webchat), in 109+ languages. The Artera impact: more efficient staff, more profitable organizations and a more harmonious patient experience. Founded in 2015, Artera is based in Santa Barbara, California and has been named a Deloitte Technology Fast 500 company (2021, 2022, 2023), and ranked on the Inc. 5000 list of fastest-growing private companies for four consecutive years. Artera is a two-time Best in KLAS winner in Patient Outreach.

Arterys was founded to facilitate the global advancement of medicine through data, artificial intelligence and technology. Because a significant proportion of the world's medical data resides in medical images, Arterys set out to tackle several issues around the space, including the enormous workloads radiologists face, the lack of accuracy with many of today's tools, and the need for increased consistency across practices. The company was the first to receive FDA clearance for a cloud-based product with Artificial Intelligence, and currently has 8 FDA clearances, and is active in 118 countries. Arterys continues to focus on solving some of radiology's most pressing needs. We deliver the most comprehensive set of clinical AI solutions in the industry, built off a single platform and user interface that focuses on users with seamless workflow integration and a unified and optimized UI for every one of our applications. By making imaging diagnostics quantitative, intelligent and available, we empower healthcare organizations to improve physicians' experience, patient outcomes, efficiency, and reduce costs with cloud and AI. Arterys has offices in San Francisco, Calgary and Paris. For more information, please visit www.arterys.com. Follow Arterys on Twitter at @ArterysInc at https://twitter.com/ArterysInc.

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

At Athelas we're bringing simple, life-changing health care products and medical billing services to patients and providers around the globe. Athelas Revenue Cycle Management (RCM): Billing and reimbursement don't have to be painful. Athelas RCM delivers world-class service, maximizes reimbursements, and delivers actionable insights into the financial health of your practice. Athelas prides itself on end-to-end revenue cycle management. This means we cover all aspects of RCM besides simple submission - include denials, working A/R, research, and more as the backbone of your healthcare business. Athelas has powered revenue intelligence for hundreds of healthcare businesses, from small clinics to large health systems. Athelas Remote Patient Monitoring (RPM): We allow healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for Inflammatory Bowel Diseases, lupus, and cancer. The company is focused on developing precision therapeutics for novel & specific subtypes of patients.

Developed a proprietary platform that holds the potential to discover novel structure targets across the transcriptome and for the design of RNA-targeted small molecules, RNA-based medicines and RNA tools.

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers

ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, Cell Line Development, and Master Cell Banking — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Master Cell Bank (MCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.

Augmenta Bioworks discovers new therapeutics by harnessing the most powerful force in the fight against disease: natural human immunity. Our technology pinpoints the protective immune response of individuals and translates discoveries into therapies.

Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.

Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.

Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit.

Axiom helps scientists eliminate molecular toxicity by providing the most accurate and affordable predictive models. Our proprietary dataset includes more than 100,000 molecules tested in pooled primary human liver cells, tens of thousands of molecules with pharmacokinetic measurements, and thousands of molecules with curated clinical outcome data. Axiom's AI models offer higher accuracy than advanced in vitro systems like 3d spheroids, deep mechanistic understanding which untangles mitochondrial toxicity, ER stress, ROS formation, cytotoxicity, and more, and precise risk assessment for any molecule at relevant clinical dosage and clinical exposure levels. Our models remove the need for costly physical experiments, giving more accurate and cheaper toxicity assessments, and empowering scientists to make better-informed decisions and bring safer drugs to the clinic.

Symphony Ayasdi is a FinTech company that specializes in AI-driven machine learning and data analytics solutions for financial services.

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.

BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They are focused on moving Prenatal Screening and Liquid Biopsy forward to improve disease detection.

BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Our proprietary platform, which encompasses >65M molecular measurements spanning 45+ years of human aging, unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. The company’s lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge’s preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data. BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development. At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.

BioMap is an AI for life sciences company, unmasking nature’s rules to generate proteins for a wide range of therapeutic and industrial applications. We build super-scale Foundation models supported by access to unrivaled computational power through our strategic collaboration with Baidu, with whom we share our Founder and Chairman, Robin Li. We supplement our AI capabilities with a leading team of scientists, disease experts and cutting-edge high-throughput labs which generate large volumes of high quality proprietary data for our AI models. We partner with pharma, biotechs and industry to enable their discovery ambitions across a wide range of therapeutic and synthetic biology modalities through access to our AI technology platform, with a variety of flexible collaboration models. Our mission is to leverage AI to radically improve lives.

Biomonadic is an early stage techbio startup leveraging AI and IoT to resolve critical supply chain bottlenecks affecting the cell and gene therapy (CGT). They are creating a next generation AI empowered data platform for biotech manufacturing, leveraging reinforcement learning and LLMs to augment their capabilities.

Biostate.AI is a startup founded in 2023 with the mission of developing generative AI for predictive omics analytics in the healthcare sector. They offer services such as RNA sequencing, DNA sequencing, image sequencing, image data analysis, and more. The company aims to lower costs and increase the utility of RNA sequencing for research and drug discovery.

BioTuring is an innovative bioinformatics company based in San Diego. Founded in 2016, the company has developed transformational bioinformatics platforms for sequencing data analysis, enabling scientists to gain valuable insights from biological data in an interactive, fast, and accurate approach. Its product portfolio now covers single-cell and spatial data analysis with BBrowserX, Talk2Data, Lens, BioVinci, and BioColab. BioTuring helps accelerate life sciences and nourishes computational minds.

Brightseed is a pioneer in biosciences and artificial intelligence (A.I.) that illuminates nature to restore human health. Brightseed’s proprietary A.I., Forager®, accelerates bioactive discovery, biological validation and ingredient formulation from years to months, rapidly revealing new connections between nature and humanity. Through Forager® and clinical evaluation, Brightseed partners with organizations across the consumer health continuum to offer insight into the world of bioactives and health solutions. Brightseed produces branded, proprietary, clinically proven bioactives that are sold to leading dietary supplement, food & beverage CPG, specialty nutrition and medical food companies for incorporation into health beneficial consumer products. Visit www.brightseedbio.com to learn more.

Buck Institute for Research on Aging is a biomedical research institute focused on studying the aging process and its effects on health.

Caption Health has been acquired by GE HealthCare. Follow us at @GEHealthCare and @CaptionCare for the latest updates and healthcare news.

At Caresyntax, we are dedicated to making surgery safer and smarter. Our mission is to converge AI-powered software, devices, and clinical services to help our customers improve surgical outcomes. Our platform, an enterprise-grade surgical intelligence system, is vendor-neutral and equipped with proprietary software, hardware, and advanced AI capabilities. It can ingest and analyze data throughout the surgical workflow, including EMR, video, audio, image, device data, financial and outcomes data, and clinical and operational metrics to capture a complete picture of the surgical pathway. The platform generates insights across the entire continuum of care—before the procedure with surgical workflow optimization, during surgery with real-time clinically relevant support tools, and post procedure with clinical safety modules. The platform also produces data analytics and insights for medical device companies, insurers, and other ecosystem players to innovate and drive the future of healthcare delivery. Headquartered in the US in San Francisco and internationally in Berlin, Caresyntax software is used in over 3,000 ORs globally and aids surgical teams in over 3 million procedures annually. To learn more about how we're transforming surgical care, visit us at www.caresyntax.com.

Cellibre is a best-in-class manufacturing technology company.. Employing an organism-agnostic approach, we turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Our world-class scientific team has led programs from napkin to commercial, pioneering revolutionary breakthroughs in energy, ingredients, medicines and more. Member: BioMade, Defense Industrial Base Consortium (DIBC)

Cercle is an AI technology company with the mission to advance healthcare for all women. With AI, we harness anonymized, diverse and reliable biomedical and genomics data from around the world to deliver unprecedented and secure healthcare insights. The Cercle™ Biomedical Graph is a first-of-its-kind knowledge graph. It uses AI to analyze billions of anonymized data points securely drawn from hospitals, clinics and research labs from all over the globe. We're turning raw, unstructured and disconnected biomedical and genomics data into clear insights for doctors, hospitals, research centers, pharmaceutical companies, labs and clinics so they can treat patients more effectively. That's how we support innovation and advancements in treatments and healthcare outcomes across the entire healthcare ecosystem. Women's health is the most underserved healthcare market, which is why Cercle's first focus will be fertility and IVF. We're proud to beta launch Luce, a fertility companion for women and doctors that analyzes data from thousands of treatment cycles to help people make more informed decisions for their fertility journeys. Cercle's suite of products includes: — Data access tools: Researchers and lab directors can query and visualize structured biomedical and genomics data to accelerate health innovation. — Modeling and insights products: Advanced modeling tools help healthcare providers with financial and operational strategies. — Tools for clinicians: Doctors get personalized care insights and predictive treatment outcomes based on Real World Data and Real World Evidence. — Patient companions: Patients get clear, data-driven insights that make it easier to understand their health and make informed decisions with their doctors. Cercle is built by medical professionals, molecular biologists, data scientists, engineers and business entrepreneurs dedicated to unlocking a world where everyone feels informed, empowered, and in control of their own health.

Certis Oncology is a life science technology company committed to realizing the promise of precision oncology. Certis was founded in 2016 with a singular purpose: to bring certainty to the fight against cancer. Their science delivers clinically relevant, predictive data and they are located in the heart of San Diego's Life Sciences center, Sorrento Valley.

ChemDiv, a fully Integrated Target-to-Market Contract Research Organization (CRO) headquartered in San Diego, CA USA. ChemDiv provides integrated drug discovery and early clinical development deliverables by extracting added value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital. - 25 years experience and 2500 customers worldwide - Premium R&D CRO based in USA with global reach - Seasoned project managers - Extensive Academic partnerships - Flexible business models - Competitive pricing options - Industry's largest ever-greening stock compound inventory - Ongoing investments in novel proprietary chemistry and discovery platforms One of the oldest CROs in the industry, ChemDiv provides Integrated Discovery outSource™ solutions that cover the complete range of disciplines needed to bring new drugs for treatment of CNS, oncology, inflammation, metabolic and infectious diseases from target to candidate and through clinical Proof of Concept to the market. ChemDiv champions collaborative development models with co-investors to rescue under-exploited R&D assets for pharmaceutical and biotech partners. #pharma #biotech #chemistry #screening_Libraries #drug_discovery_services

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. They recently raised Series B and Series C financing from The Column Group and NextTech Invest. Circle Pharma design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. They do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). They have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners. Circle Pharma workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. They deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.

Citrine empowers product experts with vanguard AI technologies. With no background in data science, product experts apply Citrine to deliver next generation products faster than any other time in history. Citrine’s software learns easily from the knowledge of its users and their idiosyncratic data to enhance all aspects of the product lifecycle across all industries with a physical product. Citrine’s users increase supply chain efficiency, rapidly improve product quality, enhance customer experience, expand product reach and increase the velocity of product delivery. With Citrine, product experts unlock the capability to solve our society’s greatest environmental and productivity challenges. Citrine's customers include Eastman, Panasonic, Grace, LyondellBasell, LANXESS, Morrow Batteries and some of the biggest and most respected names in the materials and chemicals and CPG industries in Asia, North America, and Europe. For more information visit our website at https://citrine.io.

Clarity Genomics provides consulting services for microbiome-metabolome data insights in clinical research. Using our global network of specialists and regional cloud storage and computing, we provide expertise in collection and preparation of microbiome and metabolome samples, data processing and analysis. We work closely with our clients to offer biological insights that empower the development of new microbiome products and therapies. Partnerships with leading research institutions ensure that your project receives relevant information utilizing technologies and techniques on the forefront of innovation.

We're a dedicated team of engineers, data scientists, doctors, innovators, and creative thinkers from across the globe. We're united in our drive to use technology to simplify healthcare and make it work better for everyone involved. We unify all data sources and other systems together for a complete picture. We automate for efficiency throughout. Clinical, operations, and financial results are collected and coordinated like never before.

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.

Cognoa innovates solutions for child developmental health. We build breakthrough products like Canvas Dx, the first and only FDA authorized autism diagnostic for children ages 1.5 to 6 years that uses responsible AI to empower doctors to quickly, accurately, and fairly diagnose developmental risk without bias. Our digital solutions are child centric and designed to find, assess, and treat developmental concerns early, within the time windows that will yield the optimal outcomes. Our proprietary "whole child" approach to AI fuels our pipeline of diagnostic and therapeutic products for autism, speech and language, ADHD, childhood anxiety, and more. For more information, visit www.cognoa.com.

Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

Collaborative Drug Discovery's CDD VAULT is a hosted biological and chemical database that securely manages your private and external data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy-to-use web interface. The available modules within CDD Vault include Activity, Registration, Visualization, Assays, AI, Automation, Curves, Inventory, and Electronic Lab Notebook (ELN). Each module is designed to optimize various aspects of research and data management, enhancing the overall efficiency and productivity of scientific workflows. CDD Vault is a system your entire team can actually use! Engineered for Ease of Use CDD Vault allows you to enjoy the benefits of large enterprise systems without the administrative burden or expense. Modern Cloud Solution Saves Money CDD Vault is affordable to academic laboratories, research foundations, and small companies. Beats Juggling Spreadsheets of Screening Data! Eliminates the Risk of Data Loss CDD Vault provides a secure environment to collect all your compound and screening data. Get Better Results from Unified Data CDD Vault consolidates all your compound and screening data in one place. This makes analysis easier, more consistent, yielding results more quickly. Securely Store Experimental Data in a Private Hosted Vault Data Migration is a Snap CDD Vault can provide easier access and better management of your existing data too. Safely Share Data CDD Vault allows you to selectively share data in real time with your designated researchers in your own lab or across the globe. Security is Built-In - CDD Vault is protected with SSAE 16 Type II certified cloud storage on locked and guarded hardware. https://www.collaborativedrug.com/pages/benefits CDD VAULT from Collaborative Drug Discovery https://www.collaborativedrug.com

Genetic testing, direct to consumerCOVID-19: EUA (05/2020) for their LAMP (Loop-mediated amplification) and uses three SARS-CoV-2-specific primer sets targeting the SARS-CoV-2 nucleocapsid gene (N), the envelope gene (E), and the ORF1a region.

Conversio Health is an innovative chronic condition management company focused on COPD and Asthma Disease Management. They aim to improve outcomes, prevent hospitalizations, and reduce the total cost of care for chronic respiratory conditions.

Cortechs.ai develops and markets cutting-edge imaging solutions that are used by radiologists, neurologists, and oncologists in hundreds of clinics and research centers around the world. The Cortechs.ai team includes scientists, engineers, business professionals, and clinical specialists working towards the common goal of improving the diagnosis and treatment of patients with neurodegenerative disorders and cancers. Cortechs.ai's​ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician's desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer's disease, multiple sclerosis, epilepsy and traumatic brain injury.

Cortex aims to transform the diagnosis and treatment of atrial arrhythmias by providing insight into each individual patient's disease pathophysiology. The OptiMap™ System is a 510k cleared, electrographic flow mapping solution designed with AI, enabling physicians to See What Matters.

Reinventing drug development from the ground up and making on-demand oligonucleotide therapeutics possible.

Cyclarity Therapeutics, Inc. is pursuing a mission to treat, cure, and reverse atherosclerosis. The company aims to deliver simple and affordable therapies for cardiovascular disease and other chronic diseases of aging. Cyclarity is continuing to develop technology to treat the underlying causes of age-related diseases.

Cytonus is reinventing drug-discovery and drug-delivery by questioning the principled approaches of pharmacodynamics (physiological effects of drugs) that has failed patients since the start of medicine. With a revolutionary platform technology called the Cargocyte, we believe the days of flooding the body with medicines with a hope and prayer to effect disease is not only antiquated, it is scientifically flawed. With a combination of precision drug delivery and in-vivo drug production the Cargocyte platform enables science and medicines to new level of effectiveness without compromising safety for patients.

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale

Darmiyan is a pioneering brain technology (deep-tech) company based in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company's mission is to enhance brain health, equipping physicians with tools for precise, personalized patient care, thereby optimizing health outcomes. Darmiyan's first product, BrainSee, is FDA-approved and available to physicians to aid in prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI).

The BIOVIA portfolio integrates the diversity of science, experimental processes and information requirements, end-to-end, across research, development, QA/QC and manufacturing. Capabilities include Scientific Informatics, Molecular Modeling/Simulation, Data Science, Laboratory Informatics, Formulation Design, BioPharma Quality & Compliance and Manufacturing Analytics.Subsidiaries: Accelrys Ltd, Synomics Ltd, VelQuest Corporation, others.

Deep 6 AI is a clinical trials software company based in Pasadena, California, founded in 2016. The company focuses on accelerating patient recruitment and enhancing clinical research through AI-powered analysis of real-world clinical data. In March 2025, Deep 6 AI was acquired by Tempus, further integrating its capabilities into Tempus' healthcare ecosystem. The company specializes in AI-powered patient matching, which analyzes both structured and unstructured electronic medical record data to identify eligible patients for clinical trials. Its platform connects healthcare organizations, researchers, and life sciences companies, streamlining trial workflows. Deep 6 AI also generates real-world evidence to support rapid clinical trial feasibility analysis and data-driven protocol design, utilizing natural language processing and machine learning to process data from over 25 major healthcare organizations.

Deep Apple Therapeutics is writing a new playbook for drug discovery, leveraging a powerful combination of cryo-EM enabled structural biology, AI-powered pocket extraction, and more. The company is advancing multiple programs focused on GPCR modulators, a proven target class with applications in metabolic disorders.

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

Diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, and cell and gene therapy.

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

DynoSense Corp. is a medical technology founded by successful high tech veteran, with a mission to “innovate best in class products and services for better, longer, and healthy life that are integrated, accurate, secure, elegant, and simple to use”. We call it “Innovation For Life”.

Edeniq, Inc. is a leading biotechnology company specializing in innovative, analytical solutions for the biofuels industry. With a focus on the analysis of fiber and cellulosic ethanol, Edeniq helps its customers quantify and qualify increased yield value and reduced carbon intensity, and optimize plant operations. Founded in 2008, Edeniq’s experienced team and strong customer focus have established the company as the top analytical testing service provider for ethanol producers across North America. Learn more at www.edeniq.com.

Eigen Therapeutics is a biotechnology company developing therapies that make cancer easier to find and eliminate. Eigen is focused on the development of 'priming' therapies that improve efficacy while reducing the toxicity of small molecule therapies.

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. They are pioneering a new method of drug discovery based on tracking and measuring movement of molecules within living cells. The company leverages superior engineering and high-performance computing to analyze single molecules and discover innovative medicines.

We are a skincare startup founded in 2018 in San Francisco. We combat the rise of skin conditions and sensitive skin by building a world in which beauty and science work together to produce optimal health. We develop clean, science-backed products that respect our skin's natural ecosystem. Discover our B2B microbiome tech platform @hellobiome. Our founder, Elsa Jungman, has a Ph.D. with strong expertise in dermatology, microbiome and clean beauty. She is a UCSF, L'Oréal and AOBiome alumna.

Emerald Cloud Lab® (ECL®) provides researchers from various disciplines with access to state-of-the-art scientific labs from anywhere on earth, 24 hours a day, 365 days per year. With ECL researchers utilize a single software interface to securely design, run, and analyze experiments, allowing researchers to spend more time designing protocols and analyzing data, and less time on mundane time-intensive activities in the lab. With ECL every researcher utilizing the platform becomes more productive, and more efficient while reducing operational costs and the impact on the environment.

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn’t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.

Evidation creates new ways to measure and improve health in everyday life—making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe.

Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company's proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio was founded with technology from the UCSF laboratory of Dr. Hani Goodarzi, and consists of veteran leaders in the RNA biology, liquid biopsy, and artificial intelligence/machine learning fields from both academia (UCSF, Stanford, MIT) and industry (Bluestar, CareDx, Evidation, Google, 23andMe, Deep Genomics). Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies. We know that people are our greatest asset and we are rapidly building a rock-star team of talent. Our people are driven by the mission, inspired by the vision of the future, and are committed to living our core values (integrity, openness, teamwork, exploration, and kindness) that connect us to our work and to one another. What We Value Our core values represent what we stand for as a team. This is what we believe in. Everyday, we strive to align our behaviors to these core values in everything we do. Integrity – Our thoughts and actions are true to science and to people. We do the right thing. Openness – We recognize and respect our differences – and embrace learning from them. Teamwork – We are team players who trust and respect each other. Exploration – We are explorers, putting curiosity into action. Kindness – We are kind whenever possible – and we believe it's always possible.

Fauna Bio is inspired by the untapped potential of non-model organism biology. We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.

Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.

Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.

GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach, which accelerates therapeutic development with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid novel target identification/verification, and drug discovery/development. GATC Health envisions the future of medicine now, where disease is reversed safely so everone can live their best lives.

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.

Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020). Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.

Our mission is to use visionary science and technology to overcome major unsolved diseases.

Process, analyze, and annotate genomics and biomedical data at scale using containerized workflows.

Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, let's transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Automate and scale your participant recruitment and engagement with the Grove AI Assistant and PRM™. Our AI assistant is available 24/7 and adapts to every trial, ensuring the right participants are connected to the best clinical trials.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions.

HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide. Cleared for use in the United States, Canada, Europe and Japan and with offices in Redwood City, Austin, London and Japan, HeartFlow's footprint is growing rapidly. HeartFlow has received more than $240 million dollars in funding in a recent Series E financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics. We try to embody the best of both technology and healthcare companies and hire people who are passionate about living our mission to save lives, improve the patient experience and reduce the overall cost of care. For more information, visit www.heartflow.com.

Vista.ai is harnessing the power of artificial intelligence (AI) to offer clinicians an easy, cost-effective and stress-free way to conduct MRI studies. The company's FDA 510(k) cleared MRI CoPilot™ software-only solution automates and dramatically simplifies a CMR exam, enabling any MRI tech to perform a CMR in a standard mixed-use scanner time slot. Available for use on Siemens Healthineers and GE Healthcare MRI scanners, MRI CoPilot™ • Eliminates the need for specialized CMR technologist • Allows CMRs to fit into your mixed-use scanner standard time slot • Makes scans less stressful for the technologist • Gives patients greater comfort and convenience Vista.ai is funded by Khosla Ventures, and the National Institute of Health's Small Business Innovation Research program.

Hexagon Bio is a biopharmaceutical company pioneering the discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Leveraging a proprietary platform, the company mines cytotoxic small molecules from microbial genomes for use as ADC payloads. Advances in DNA sequencing have enabled the identification of both existing ADC payloads—such as topoisomerase and tubulin inhibitors—and novel payload mechanisms targeting essential cancer pathways such as protein translation. Hexagon Bio is advancing a pipeline of next-generation ADC candidates with novel payloads designed to treat a wide range of solid tumors and hematological malignancies.

Hippocratic AI’s mission is to develop the first safety-focused Large Language Model (LLM) for healthcare. The company believes that a safe LLM can dramatically improve healthcare accessibility and health outcomes in the world by bringing deep healthcare expertise to every human. No other technology has the potential to have this level of global impact on health. The company was co-founded by CEO Munjal Shah, alongside a group of physicians, hospital administrators, healthcare professionals, and artificial intelligence researchers from El Camino Health, Johns Hopkins, Washington University in St. Louis, Stanford, Google, Microsoft, Meta and NVIDIA. Hippocratic AI has received a total of $137 million in funding and is backed by leading investors, including General Catalyst, Andreessen Horowitz, Premji Invest, SV Angel, NVentures (Nvidia Venture Capital), and Greycroft.

The Future of Microsurgery is Robotics and AI. Horizon Surgical Systems, founded in 2021 by experts in ophthalmology and medical robotics, is at the forefront of innovation in microsurgery. Our groundbreaking product, Polaris, leverages state-of-the-art robotics, advanced medical imaging, and AI to extend the capabilities of surgeons beyond their current limitations. With a foundation rooted in academic excellence and a vision for the future, Horizon is committed to revolutionize global healthcare through technological innovation, bringing a new era of precision, enhanced outcomes, and safety to eye care.

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

ImmunoMind is a UC Berkeley SkyDeck alumnus company, focused on understanding drug-human interactions to create more effective immunotherapies for underserved populations.

ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.

INanoBio’s mission is to develop high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning. Extract systems scale information from complex disease biology, identify and detect disease specific molecular biomarkers, signatures at prodromal or pre-symptomatic stages. We believe most diseases can be detected early, enabling early personalized therapeutic intervention to preempt full development of diseases, ushering in preemptive medicine.

Biological Software is one or more synthetic molecules that execute complex functions, specified from a program, in a biological system. We are creating tools to develop increasingly powerful biological software for the rational design of novel, broadly accessible medicines and biotechnologies previously out of reach. Our antedisciplinary team of scientists, machine learning researchers, engineers and entrepreneurs is growing. If you are excited to learn, teach, discover, and create together in pursuit of learning life's languages to improve the lives of billions of people around the world, please visit our website.

Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions. *Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding.

Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California. To learn more, visit Inscripta.com and follow @InscriptaInc.

Buys life science software companies.

InsightRX empowers life science and provider healthcare organizations to individualize treatment from clinical development to the point of care.

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We’re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.

We combine synthetic biology and machine learning to control cellular stress responses for next-generation therapeutics.

InterVenn was co-founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist, and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease. We are focused on decoding the glycoproteome as a rich source of biological insight. Thanks to the use of artificial intelligence (AI), we have pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology at a clinically meaningful scale. GlycoVision is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. The GlycoVision platform is accessible to industry partners seeking to discover novel biomarkers from as little as 50 µL of serum or plasma.

Invenio Imaging is a medical device start-up based in Santa Clara, CA dedicated to advancing the care of cancer patients by combining intraoperative histologic imaging with artificial intelligence. Our technology, the NIO® Laser Imaging System has been used in over 2500 cancer treatment procedures at major cancer centers both in the US and in Europe. In 2021 Invenio received a Medical Design Excellence Award, was selected to be a Rosenman Innovator and received CE Mark to commercialize in Europe.

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis. With MIBI technology and the expertise of world class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharma, biotech, and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research.

FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company's consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.

The iSono Health has developed the world’s first AI-driven platform with an automated, portable, and wearable ultrasound to empower women and their physicians with early breast cancer detection and monitoring. Our patented compact ultrasound scanner captures 3D images by automatically scanning the whole breast volume in 2 minutes. The device connects to a smartphone/tablet/laptop. The data is transferred to a secure cloud for image processing and storage. Our machine-learning algorithm uses acoustic biomarkers to identify abnormal masses. Our platform’s automated operation and software expand ultrasound use in point-of-care diagnostics and monitoring of breast health at radiology centers, walk-in, and mobile clinics. iSono Health offers women and healthcare providers : Safety: No Radiation Actionable Feedback with AI Fast: 2min Scan Easy to Use

We are on a mission to create the next century’s worth of impact on human health, starting with early detection. Since our founding in 2018, we have been operating at the convergence of artificial intelligence, transcriptomics and liquid biopsy — applying the most advanced compute to the most fundamental language of the human cell to create the world’s most advanced early detection blood tests. Our disease-agnostic platform is revolutionizing healthcare diagnostics, providing a reliable and scalable approach to solving real-world problems for pandemic diseases, from oncology to metabolic health. To date, our brain trust of visionary entrepreneurs and world-class scientists and technologists have conceived, created and scaled three pioneering early detection companies — @mammogen, @liquidlung & @hepgene — leveraging our novel end-to-end AI-powered platform to usher in a new era of clinical assays capable of detecting early-stage disease with unprecedented accuracy, affordability and accessibility. To learn more about us visit IVBH.studio or send us a note at info@IVBH.studio.

JADBio’s purpose-built AutoML platform provides leading-edge AI tools and automation capabilities enabling life-science professionals to build and deploy accurate and interpretable predictive models with speed and ease, even if they have no data science expertise. For life-science professionals, knowledge discovery is fundamental and sets the requirements apart when it comes to data analysis. JADBio can analyze small sample sizes or very large feature sets, focusing on feature selection and interpretation of the predictive model.

Jan Medical is a medical device start-up company dedicated to providing physicians critical data for accelerating and expanding therapy while improving the diagnostic experience for patients with brain disorders. Its proprietary platform technology, BrainPulse, uses accelerometers on a non-invasive headset to detect skull motion resulting from pulsatile blood flow into the brain. The BrainPulse system is an FDA cleared device for cranial motion measurement currently under research for a variety of neurological conditions. Jan Medical has developed clinical experience and collected valuable clinical data with the BrainPulse device in a variety of indications such as concussion, stroke, aneurysm, AVM, and vasospasm detection. Visit us at www.janmedical.com to better understand our company, our technology and our people.

Junevity is a biotech rewinding complex metabolic disease. Based on 6 years of breakthrough research at UCSF, Junevity's REWIND platform identifies high-level regulators of metabolic disease with known pharmacological pathways. Junevity is advancing multiple therapeutic programs towards a new era of medicines.

Juvena Therapeutics is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions.

Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.

Kerna Labs is unlocking the full potential of mRNA as the universal toolkit for genetic medicine.

Kimia Therapeutics is generating a chemical atlas for treating human disease. Kimia's ATLAS is the key to druggable space, unlocking the potential of generative chemistry. The company is focused on drug discovery and developing disease-modifying therapies for metabolic diseases.

Koliber Biosciences is a biotechnology company that accelerates biomedical discoveries using machine learning and artificial intelligence.

Laza Medical is a healthcare technology company based in California, founded in 2020. As a portfolio company of Shifamed, it focuses on developing innovative solutions for cardiovascular interventions. The company specializes in AI-powered robotic assistance technology, which enhances medical imaging and procedures. Laza Medical's main offering is an advanced imaging solution that supports cardiovascular interventions. This solution utilizes AI and robotic technology to provide navigation tools for structural heart and electrophysiology procedures in cath labs. The company aims to improve the precision and efficiency of these medical procedures through its technology. In December 2023, Laza Medical raised $36 million in a Series A funding round, led by The Capital Partnership, with participation from investors like Unorthodox Ventures and GE Healthcare Financial Services. With its innovative approach and strong funding support, Laza Medical is positioned to make a notable impact in the medical technology field.

LifeAdapt is at the forefront of AI technologies that promote healthy living.

SVBio is now LIfecode, Inc. We are focused on the genetic basis of human disease. With an initial focus in oncology, Lifecode is committed to improving the lives of patients through molecular information that is concise, accurate and actionable. The long-term vision of Lifecode is to revolutionize the world of genomic medicine.

LifeMap Sciences offers a leading integrated biomedical knowledgebase for empowered life sciences research and precision medicine, and a powerful advertising products for research reagents. Our products are used by more than 5 million researchers from both academia and the biopharma industry. GeneCards (www.genecards.org) is a searchable, integrative database that provides comprehensive, user-friendly information on all annotated and predicted human genes. The knowledgebase automatically integrates gene-centric data from ~150 web sources, including genomic, transcriptomic, proteomic, genetic, clinical and functional information. MalaCards (www.malacards.org) is an integrated database of human maladies and their annotations, modelled on the architecture and richness of the popular GeneCards database of human genes. Today, it offers information about 22,060 disease entries, consolidated from 74 sources

Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies. Given that increasingly complex disease states require precise and custom-tailored medicine, much of our technology development has focused on combining gene therapy with targeting peptides to enable completely new paradigms in evolutionary medicine. Currently, we are utilizing a peptide nanoscaffold based approach for treating COVID-19 without a gene therapy component, with the goal of creating a combined antidote-vaccine. My expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. At Ligandal, we have demonstrated peptide-based delivery of CRISPR, RNA, DNA, siRNA, and a range of genes or proteins to virtually any cell type.

Livongo is now a part of Teladoc Health. Teladoc Health is transforming the healthcare experience and empowering people everywhere to live healthier lives. Recognized as the world leader in whole person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person's health journey. In more than 175 countries and ranked Best in KLAS for Virtual Care Platforms in 2020, Teladoc Health leverages more than a decade of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.

LTZ Therapeutics is an immunotherapy-focused global biotech company pursuing innovative therapies in oncology and autoimmune diseases. Pioneering a novel myeloid engager platform that is guided by reverse translational science, emerging disease biology, and leveraging the power of myeloid cell subsets, particularly macrophages, which offer tremendous potential as an effective therapy to improve the lives of patients with the bold aim to one day eliminate cancer.

LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company's diagnostic solutions are designed to make a significant impact in the early detection of lung cancer. The Company's technology is a combination of the recovery of rare cells and blood-based biomarkers shown to be altered in lung cancer. The Company employs machine learning to improve biomarker detection, and intends to build a deep, novel pool of lung cancer-related data for AI-enabled applications designed to improve its diagnostic solutions over time. The Company's core technologies are integrated in the LungLB® test, which is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules that may be lung cancer following a CT scan. There are estimated to be over 1.5 million individuals with indeterminate lung nodules diagnosed each year in the United States. The LungLB® test may have additional utilities, the most significant of which is likely to be in monitoring individuals for recurrence following surgical removal of cancerous lung nodules. The Company has completed a 149 subject pilot study to evaluate the LungLB® test, which showed a well-balanced performance and a Positive Predictive Value of 89 per cent. The Company is now gearing up to proceed to a larger, multi-centre validation study to garner regulatory and reimbursement support and facilitate commercialisation.

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

Mana.bio is an AI based drug delivery startup, creating a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including mRNA-based therapeutics, vaccines and gene therapy.

Mateon Therapeutics is developing OXi4503 for the treatment of acute myeloid leukemia. OXi4503 has a unique dual mechanism of action which causes the release of leukemic stem cells from the bone marrow and enables their destruction.The company is also using artificial intelligence to develop treatments for coronavirus.

Medeloop accelerates breakthrough discoveries through novel deep AI model explainability techniques built on top of a comprehensive data linkage infrastructure. Medeloop is a one of a kind platform that seamlessly links, harmonizes, and analyzes massive amounts of health data. We are pioneering AI techniques that find biomarkers for clinical researchers, helping break down barriers to save lives. For Researchers: Our platform shortens the clinical research process using advanced AI techniques that provide research hypotheses for even the most understudied diseases. All of your data, all in one place. Cleaned, organized and analyzed. Medeloop transforms the research approach, enabling researchers to publish more and publish faster. For Research Participants: Our patient-facing app encourages the public to take control of their health and contribute to life-changing medical research. You always have access to view your health information and how it is being utilized.

Melio is developing a clinically actionable fast and comprehensive test for all common infections

MemVerge is a pioneering developer of software for Big Memory Computing. In the cloud or on-premises, data-intensive workloads run faster, cost less, and recover automatically with the company’s award-winning Memory Machine™ products. Memory Machine X is poised to revolutionize how CXL® memory will be used in the future, while Memory Machine Cloud stands out with its ability to continuously right size cloud cost and performance. Learn more about MemVerge and its Memory Machine software at www.memverge.com.

Mendel AI is the only clinical AI platform that performs clinical reasoning to supercharge clinical data workflows. Powered by coupling large language models with a clinical Hypergraph, Mendel's AI copilots, known as Hypercubes, offer clinically trustworthy and explainable insights, streamlining tasks like cohort building, chart review, and data discovery. Mendel's solutions cater to biopharma, providers, and diagnostics, integrating seamlessly with existing tools and delivering proven results We strive for excellency, to be authentic and original, and to make a difference by greeting our challenges head on. Please visit our website, mendel.ai, to learn more about our company, goals, and values.

Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

Mindera Health™ is commercializing scalable extraction technology and data analysis to report a patient’s individual transcriptomic data. Mindera’s technology creates Dermal Intelligence™, actionable information for payers, providers and patients. The company’s flagship test, Mind.Px, uses both a dermal biomarker patch and Machine Learning to determine a patient’s receptivity to very expensive psoriasis biologics. This information is valuable to payers, who can save thousands of dollars per biologic patient using Mind.Px at the outset of prescription. Mind.Px is the first test in a large planned product pipeline, including psoriatic arthritis and eczema biologic receptivity.

Mirador Therapeutics is a next-generation precision medicine company focused on immunology and inflammation. The company's Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to accelerate the next generation of precision medicines for immune-mediated diseases.

We're Mirai Bio, biotech's first open end-to-end development platform company for co-creation of optimized #GeneticMedicines. Learn more at MiraiBio.com.

Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs. The company was founded in 2019 to deliver on the promise of AI-Drug discovery. With more than 182 compounds for 26 targets, they are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA.

Modulo Bio simulates the neuroimmune system to find medication candidates that target microglia cells. The organization's proprietary neuroimmune system mapping platform is designed to identify potential treatments for neurodegenerative diseases such as ALS and FTD.

We are a tech-centered, animal diagnostics company on a mission to help veterinarians lengthen the lives of their patients by applying deep learning to the diagnostics they use daily.

Moonwalk Biosciences is an early-stage therapeutics company co-founded by Dr. Feng Zhang and leading experts in cell state epigenetics including Alex Aravanis, the former CTO of Illumina. The company has developed a differentiated approach to mapping the epigenome of cellular states at the whole genome, single cell resolution level, as well as proprietary strategies for precise epigenetic engineering. The combination enables both a novel discovery platform and a path to developing therapeutics that include both epigenetic engineering and other traditional modalities.

Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

At NextGen Jane, we believe in enriching your Quality of Life, expanding your Agency, and enabling your Pursuit of Data. All good revolutions are anchored in coherent philosophies championed by an impassioned base. This is our revolution, to empower women with the information needed to make smart decisions and take true health ownership. Armed with our SmartTampon platform that serves as a sentinel system for your reproductive health, we hope to impact how you manage your health, from menarche to post-menopause. If you dig it, join us. It is hard to create new ways of engaging with our health in rigid systems within a complex care system, but not impossible. Help us re-engineer our future, in our image.

Noah Medical is a medical technology company based in San Carlos, California, founded in 2018. The company specializes in developing advanced medical robotics aimed at enhancing diagnostic procedures in pulmonology. Its flagship product, the Galaxy System, is a robotic platform that integrates real-time navigation, augmented fluoroscopy, and tomosynthesis to improve the accuracy of lesion localization, which is vital for early lung cancer diagnosis and treatment. With a team of over 150 engineers and industry experts, Noah Medical leverages extensive experience from leading healthcare companies. The company's mission focuses on saving lives through early diagnosis and treatment, particularly in robotic navigated bronchoscopy. Noah Medical has received recognition as a "Fierce 15" company of 2023 and has raised $150 million in funding to support its innovative approach. Its technology is designed to enhance procedural efficiency and diagnostic accuracy in healthcare facilities, particularly in pulmonology and oncology.

Nobias Therapeutics is a clinical-stage company developing novel small molecule therapeutics for rare diseases. Our unique access to rich genomic and health datasets and strong relationships with pediatric academic medical centers across North America allow us to rapidly advance drug discovery for genetically-defined rare diseases, with an initial focus on pediatric indications, but expansion opportunities in adults and non-rare indications.

Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies.

Northrop Grumman solves the toughest problems in space, aeronautics, defense and cyberspace to meet the ever evolving needs of our customers worldwide. Our 95,000 employees define possible every day using science, technology and engineering to create and deliver advanced systems, products and services.

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community. Notable's proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product's medical impact and commercial value faster, higher, and more likely than traditional drug development.

In 2023 NeuraSignal, Inc. acquired the business of NovaSignal, the original developer of NovaGuide. NeuraSignal is a medical technology company with a mission to save lives by unlocking the power of cerebral blood flow data. The company's FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time. Using cloud computing and data analytics, NeuraSignal supports physicians in their clinical decision making in several neurological conditions including stroke, traumatic brain injury, and dementia. To learn more, visit www.NeuraSignal.com.

NuMedii is a biopharmaceutical company that discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success.

Octant is a well-backed team of experienced scientists and entrepreneurs exploring new frontiers of biology. We are applying next-generation DNA sequencing, gene synthesis, and gene editing to revolutionize drug discovery in a quest for safer, more effective, and cheaper drugs.

Olio labs uses AI and ML to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. The only way to build and test the number of combinations required to find a better treatment is to automate as much of the therapeutic discovery and development pipeline as possible. We are a new type of scientist that is comfortable working at the bench and in the code base. Our custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one. We are currently backed by the amazing investors at SciFounders and YCombinator.

OmniAb is a leading-edge antibody discovery company that provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening. The company's discovery platform brings a high level of expertise and innovation to therapeutic antibody discovery.

OmniTier Inc. develops easy to use, end-to-end, genomic analysis on-premise and cloud based systems that achieve greater accuracy and faster run-times than competing offerings.

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

Oncobox is transforming cancer care with precision medicine by leveraging the power of artificial intelligence and systems biology. Through the integration of deep molecular profiling—which includes analysis of not only DNA mutations (exome) but also RNA gene expression (transcriptome)—and comprehensive data analytics, we achieve unmatched precision in identifying the most effective treatment strategies, markedly improving outcomes for patients battling late-stage cancers. The effectiveness of Oncobox's technology is backed by both prospective and retrospective studies. This approach has shown remarkable success, leading to a twofold decrease in disease progression and a significant increase in progression-free survival (PFS). Oncobox's innovative use of deep molecular profiling is setting new standards in the precision and efficacy of cancer treatment.

OptraHEALTH® is at the forefront of healthcare innovation, leveraging cutting-edge Artificial Intelligence to transform patient care and streamline operations for providers and payors alike. At the heart of this revolution is our flagship AI platform, HealthFAX™. HealthFAX™ isn't just another healthcare tool—it's a comprehensive AI ecosystem designed to redefine the entire patient journey. From the moment a patient considers seeking care to long after their visit, HealthFAX™ is there, invisibly orchestrating a seamless, efficient, and patient-centric experience. Imagine a healthcare world where: * Digital front doors welcome patients with personalized, AI-driven guidance * Intake processes are streamlined, reducing wait times and frustration * Intelligent triage ensures patients receive the right care at the right time * Accurate cost estimates eliminate billing surprises * AI-powered patient counseling provides round-the-clock support * Insurance information is clarified with ease, reducing administrative burdens But HealthFAX™ doesn't stop there. Post-visit, our AI continues to work tirelessly: * Automating report analysis for faster, more accurate diagnoses * Managing follow-ups to ensure no patient falls through the cracks * Providing actionable insights to continuously improve care quality In the age of value-based care and the No Surprises Act, HealthFAX™ is more than a technological advancement—it's a strategic imperative. By automating complex processes, ensuring regulatory compliance, and enhancing communication at every touchpoint, HealthFAX™ allows healthcare organizations to focus on what truly matters: delivering exceptional patient care. Join the AI-driven healthcare revolution with OptraHEALTH®. Together, we're not just improving healthcare—we're reimagining it.

As a global leader in digital pathology, OptraSCAN is dedicated to revolutionizing diagnostics and patient care through advanced technology. We specialize in providing cutting-edge digital pathology solutions, including state-of-the-art digital pathology scanners and whole slide imaging scanners, designed to enhance the accuracy and efficiency of diagnostic processes. Our extensive range of digital slide scanners includes brightfield slide scanners, histology slide scanners, and fluorescence slide scanners, enabling healthcare institutions to transition seamlessly from traditional microscopy to sophisticated digital pathology systems. Our whole slide scanners and digital pathology slide scanners offer high-resolution imaging that improves precision, streamlines workflows, and provides cost-effective results. OptraSCAN leads the way in digital histopathology with innovative solutions that integrate advanced artificial intelligence (AI). Our AI-powered pathology scanners and digital pathology artificial intelligence technologies are designed to boost diagnostic accuracy and efficiency. We offer comprehensive solutions including whole slide imaging scanners and computer-aided region detection systems. We are committed to making digital pathology accessible to all, providing compact and advanced scanning systems that overcome barriers to modern diagnostic methods. Our digital pathology solutions include cloud-based LIMS (CLOUDPath), image analysis tools (OptraASSAYS), and up to 10 TB of complimentary cloud storage. By choosing OptraSCAN, you partner with a leading digital pathology company that is shaping the future of diagnostics with high-quality digital pathology scanners and integrated whole slide imaging solutions. Our goal is to ensure that healthcare systems worldwide can seamlessly adopt and benefit from our transformative digital pathology technologies.

Palisade Bio (Nasdaq: PALI) is a biopharmaceutical company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care. Palisade Bio’s lead program, PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. The Company’s second lead program, PALI-1908, is being evaluated in preclinical development for the treatment of fibrostenotic Crohn’s Disease.

Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients.

Parallel is a next-generation skin health company providing effective, targeted solutions powered by microbiome science, genomics, and machine learning. At Parallel, everything we do is grounded in science and innovation. We believe that the future is precision medicine and we believe that what we’re building is vital to that vision. Here, consumers and patients can access best-in-class expertise and clinical guidance, a personalized genomic assessment to understand their skin microbiome, as well as personalized, targeted microbiome skincare products and prescriptions (if needed). With one of the largest data sets in the world on the skin microbiome, a 10,000-deep bacterial library, and patents pending, Parallel was just honored by Fast Company as a "World Changing Idea."

Persephone is pioneering the use of synthetic biology for microbial products that impact patient and infant health. We are building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler PhD, and Steve Van Dien PhD.

Neutralizing Antibody Discovery

Phythera Therapeutics, Inc. was started to test, develop and improve promising small molecule-based drugs for oncology and inflammation markets. Many small bioactive phyto-molecules used in biomedicine have been derived from plants (hence –Phythera Therapeutics). The cocktail of drugs is expected to be better than one molecule for managing complex diseases with no available treatments. The only medicine which can manage HIV is a cocktail of drugs. We have something of the same magnitude but for oncology, which is viewed as “one drug- one IND” by US FDA. We see the potential of drugs carrying many small bioactive molecules to substantially improve the treatment of cancer, either as an auxiliary or even as the main treatment method. The same is true for inflammation. Optimizing and improving these small molecules to maximize their efficacy to combat metastatic cancers, and converting them into potent and robust treatments of untreatable conditions like metastatic cancer and persistent inflammation is Phythera’s main overarching goal. We leverage our expertise in 3D cell biology and transcriptomics to test the small molecule compounds to define and improve their efficacy in 3D tissue model systems, either as a single compound or as a combination of several most potent small molecule drugs. The team’s proven deep expertise in stem cell biology enables us to study the impact of our candidate molecules on the most elusive and most malignant cancer stem cells and develop drug combinations, optimized for a specific disease. Last but not least, our team has a strong interest in regenerative medicine approaches for inducing tissue regeneration and improving tissue homeostasis, the key to wellness and enduring health. Small molecule compounds derived from plants possess many of the properties promoting tissue regeneration and modulating homeostasis in tissue. Enhancing these properties and converting them into new treatments is Phythera’s 2nd overarching goal.

Solving unmet needs in vascular access care

PinkDx is an early-stage company whose vision is to positively impact the health of women throughout their life journey. We focus on addressing the medical problems that women uniquely face by applying sophisticated scientific approaches to resolve them and provide answers that have an immediate, positive impact on their lives. Our first indication will focus on overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. Led by a team of diagnostics industry veterans, PinkDx is privately held, with funding from prominent biotechnology investors, including Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital and Mayo Clinic.

2024 marks 100 years since Hans Berger made the first EEG recording of the brain. Despite a century having passed, we still do not fully understand what brainwaves are telling us. From diagnostics to wellbeing, we are building technology that bridges the gap between research and real-world EEG applications. Foundation Model for the Brain.

Polares medical is a medical device company with a novel device for treating mitral valve regurgitation.

Polybiomics is a biotechnology company that revolutionizes the analysis of live cells by enabling simultaneous measurements of multiple cellular features from the same sample in real-time, connecting data types to create actionable knowledge.

Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology. Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood-, urine- and tissue-based diagnostic assays for oncology. Through its business operations in Silicon Valley, Houston, Shanghai, Singapore, and Boston, Predicine partners with leading biopharma companies, institutions and governments to support personalized healthcare on a global scale.

Prellis Bio is hiring Immunologists! We are expanding our Externalized Immune System, EXIS™, platform with applications in antibody discovery, immunogenicity, and vaccine screening all in the same platform. Prellis Biologics, Inc. is a privately held company based in the San Francisco Bay Area, CA. Apply at www.prellisbio.com.

Harnessing the Power of Cytokine Monitoring and Host-Response Understanding to Transform Healthcare Cytokines, pivotal biomarkers of inflammation, are essential in tracking the progression of infections, helping physicians tailor more effective treatments. Annually, over 10 million patients in the U.S. are diagnosed with infections, and the post-COVID-19 era has highlighted the value of cytokine monitoring. However, the current methodologies are costly and slow, undermining its potential. Our solution introduces point-of-care cytokine testing that matches central lab accuracy, completed in just 5-10 minutes, and at a significantly lower cost. This enables continuous, real-time monitoring, offering timely, actionable insights to both physicians and patients exactly when needed. Proactive Diagnostics is transforming how infections are assessed and managed, to improve care in several critical areas: - Enhancing clinical outcomes - Minimizing unnecessary antibiotic use - Shortening hospital stays - Reducing patient readmissions Our AI-driven, cloud-connected platform leverages unique data collection capabilities to deepen our understanding of individual host responses to various inflammatory stimuli. Such capabilities can also play a critical role in other important clinical areas such as the treatment of Autoimmune Diseases, where monitoring host response can inform therapy adjustments and drastically improve lives; or in the treatment of Cancer, where Cytokine levels can help optimize the administration of groundbreaking immunotherapies and adjust treatments to harness the immune system's power more effectively against tumor cells. This transformation in cytokine monitoring could be the key to a new era of personalized, predictive, and preventative medicine, where each patient's treatment is as unique as their response to disease.

Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Emeryville, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more about our mission to decode the language of life with AI, visit profluent.bio.

Promaxo is a medical technology company that develops and commercializes customer-centric MRI systems and MRI based technologies that enhance patients' experiences and outcomes. The Promaxo MRI system is designed for image-guided interventions including live MRI guided biopsies, treatment planning, robotic surgeries, and radiation.

Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.

PulmoSIM Therapeutics is the pharmaceutical subsidiary of VeriSIM Life, developing breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life. Our immediate focus is to address the unmet needs in pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) by targeting the underlying biology to alleviate the need of combination therapies. PulmoSIM Therapeutics' pipeline includes 2 drug assets. PT001 is a U.S. Food & Drug Administration designated Orphan Drug and has successfully completed preclinical study. PT001 has demonstrated positive efficacy with key disease-reversal data for the treatment of PAH. The monotherapy differs significantly from current PAH combination therapies by targeting the disease's underlying biology. We are working hand-in-hand with a world-class strategic advisory board and clinical and manufacturing partners to rapidly transition the program to clinical studies. PT002 is undergoing advanced preclinical study for the treatment of IPF. We leverage BIOiSIM, a first-in-class artificial intelligence bio-simulation platform to accelerate our drug development by bridging the translational gap between preclinical and clinical phases. Learn more about BIOiSIM at www.verisimlife.com. Get in touch if you are interested in learning more about our programs and working with us.

Q uses a systems biology approach called panomics to build a comprehensive, quantitative snapshot of your health by combining advanced non-invasive imaging, chemistry, genetics, vitals and your medical history.

The QTI team has been on an incredible journey, starting with a shared mission to create disruptive innovation to expand access to medical imaging while ensuring superior patient experience and improving health outcomes. We anchor our efforts in medical imaging because when the body can be scanned often and without harm, health conditions can be detected before symptoms appear. Chief among the new advancements in medical imaging is 3D body imaging. Today QTI focuses on our breast imaging technology, which is native 3D, high resolution, and generates reproducible image quality regardless of operator or breast size or tissue type. Current breast imaging paradigm leads to unnecessary concern and cost. ▪️Unlike mammography, QTI technology is effective in screening women with dense breasts, or 40% of women in US. ▪️35% of women aged 40-70 do not get screened. Of the 65% of women who get screened, 15% suffer unnecessary callbacks for ultrasounds, MRI, or biopsies. 80% of biopsies are benign. ▪️QTI’s technology can be a much-needed alternative for high risk women under 40, as cancers in younger women are usually aggressive and survival outcomes are poor. Our QT Imaging Breast Acoustic CT™ Scanner is the only true 3D imaging device, FDA cleared for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast. There is no ionizing radiation or compression like in mammography or contrast dyes injections like in MRIs. The technology uniquely quantifies breast density. Surface-to-volume ratios and volumetric doubling time growth rate can be calculated to determine significance of lesions and improve specificity. This breast scanning system gives women the choice they deserve to ensure their breast health over time; for healthcare providers, a technology that is accessible, affordable, and accurately visualizes internal structures of the breast; and, for investors, a market segment extension and a purposeful investment opportunity.

Our mission is to empower physicians with Al - saving physicians time, reducing burnout, and improving the quality of patient care.

Rancho BioSciences is a fee for service life science company leveraging open source tools and public domain data in Pharma, non-profit foundations and academia.

RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from over 10 million scans in more than 2,000 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI — where AI meets patient care.

Ravata Solutions is a fertility and reproduction company that specializes in hardware and diagnostics to transform the IVF laboratory with automated assisted reproductive technologies (AART) and enhance human disease model development for pre-clinical studies.

RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cf-RNA analysis (liquid biopsy) that form the basis of the Company’s life science research programs and product development.

Real Time Genomics develops analytical solutions that reduce the cost and complexity of extracting knowledge from raw genomic data. We deliver validated, accurate results that are redefining personalized medicine. ___________________________________________________________________________________ At Real Time Genomics, we have a passion for genomics. Our core competence is a commitment to know, anticipate and deliver to the needs of leading biological researchers. The company has deep computational expertise in algorithms, coupled with extensive product development capabilities and a seasoned commercial team with over 100 years of success in bringing genomics' innovation to the life sciences industry. Today,we offer solutions for genomic analysis to practitioners of next generation sequencing (NGS) technologies. These solutions include complete analytical platforms for genomics and metagenomics. We can install these platforms to your compute environment or provide you access to them through cloud computing.

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at saama.com.

Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding basic human biology and disease and advancing scientific discoveries to profoundly impact human health. Our track record of pioneering research spans more than 40 years and has produced breakthroughs in cancer, neuroscience, immunology and children's diseases and is anchored by our NCI-designated Cancer Center. Sanford Burnham Prebys' drug discovery center and global partnerships propel our prototype drugs and therapeutic strategies toward improving human health. A deep culture of collaboration and commitment to educating the next generation of scientists unites Sanford Burnham Prebys researchers, partners and philanthropists in a shared mission to improve human health.

Revolutionizing the healthcare industry by providing an integrated AI platform that provides personalized health recommendations based on a combination of your DNA, labs, and environmental factors. SelfDecode is the only company in the world providing ancestry-adjusted Polygenic Risk Scoring directly to the consumer. Through our R&D division (OmicsEdge), we are making precision health affordable to all by empowering organizations to easily build precision health products using our bioinformatics infrastructure. Our core abilities include ancestry-adjusted Polygenic Risk Scoring, which we license to other organizations.

Sentieon develops and supplies a suite of bioinformatics secondary analysis tools that process genomics data.

Seranova Bio is an early-stage company dedicated to the creation of groundbreaking therapeutics. Our proprietary REAP (rapid extracellular antigen profiling) technology and analytics platform enable the discovery of the functional immune interactions that drive health and disease. We were founded in 2020 by Fred Hutchinson Cancer Center professor and serial academic entrepreneur Aaron Ring. Located in the vibrant biotech hub of South San Francisco, we are proudly supported by leading investors Foresite Capital Management and The Column Group.

Serotiny is a therapeutic discovery company that designs new genes for next generation cell & gene therapies. We invent therapeutic multi-domain proteins in high-throughput by orchestrating software, mammalian synthetic biology, and therapeutic expertise. At the heart of Serotiny’s technology is a discovery platform involving the close interworking of computationally aided protein design, high-throughput cellular assays, and sophisticated data-driven analytics, which together enable Serotiny to engineer multi-domain proteins for cell therapies, like Chimeric Antigen Receptors used in CAR-T immunotherapies and second-generation Cas9-based gene editing tools, like Base and Prime Editors. Rationally designing proteins for cell & gene therapies requires a different set of constraints and design tools than enzyme or antibody engineering. These therapeutic multi-domain proteins will not be purified, they will be expressed in a human cell, and they will affect the therapeutic phenotype of that cell. Serotiny encodes these constraints into its platform to create a scaled design-build-test-learn process to quickly and efficiently generate therapeutic candidates for next-generation therapies. Serotiny is a multidisciplinary team with expertise including molecular biology, immunology, machine learning, software engineering, data science, and bioinformatics. We’re looking for passionate and creative people to join our team!

Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California. To learn more, visit Inscripta.com and follow @InscriptaInc.

Shiru is a food technology company that specializes in alternative protein and sustainable food solutions.

Siemens Healthineersenables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare.COVID-19: CE mark for its molecular Fast Track Diagnostics (FTD)SARS-CoV-2 Assay.

Simplify Genomics is a San Diego-based biotechnology company that provides clinical whole genome reporting and genome exploration at the speed of thought using its proprietary genome search engine.

Simulations Plus is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI) and machine learning (ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, and consumer goods companies, and regulatory agencies worldwide. For more information visit us at www.simulations-plus.com

Sinopia Biosciences is enabling the promise of data-driven drug discovery (D4) by applying high-throughput multi-omics data, AI/machine learning and network analyses, and disease models (genome engineered in vitro models and relevant in vivo models). It is a clinical-stage biotechnology company advancing novel therapeutics derived from its proprietary computational drug discovery platform. Sinopia’s proprietary computational platform combines high-throughput omics data, machine learning, and network biology. Sinopia is headquartered at JLABS San Diego.

Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutics to improve outcomes in conditions with unmet medical needs. Our offices and laboratory are located in San Carlos, CA.

SPOC Proteomics is a deep-tech life sciences startup based out of Scottsdale, AZ that has developed a transformative new proteomic biosensor platform termed sensor-integrated proteome-on-chip (SPOC). SPOC Proteomics offers the world’s first and only platform that provides simultaneous quantitative, qualitative, and kinetic data in a single assay at scale, to support drug and vaccine development, protein biomarker discovery, and diagnostics. SPOC enables up to 2400 unique full-length folded proteins per single biosensor chip, for simultaneous analysis using surface plasmon resonance (SPR) and up to 10,000 protein targets per chip for mass spectrometry analysis. SPOC chip proteins are produced in ~4 hours from an array of plasmid DNA with cell-free human lysate and simultaneously captured directly onto biosensor chip surfaces. This unique protein production method circumvents challenges and expense of traditional recombinant protein workflows, reducing costs 10-100x and substantially decreasing production time. Our mission is to utilize SPOC to democratize high-throughput kinetic proteomic screens and facilitate early disease detection - ultimately enabling disease preemption.

Spring gives scientists superpowers. We put world-leading technology and easy-to-use software in the hands of researchers working to understand and battle disease. Our mission is to give scientists the best tools in the world to help them fight disease. We're bringing new software, design, and machine learning tools to bear on this challenge. Our approach is to be an extension of industry partners' teams in their discovery and preclinical efforts; and to build software helping scientists comprehend and make decisions using high-dimensional data. We're hiring!

An independent non-profit institute headquartered in Silicon Valley, SRI is a global leader in research and development. We collaborate across technical and scientific disciplines to create a safer, healthier, and more sustainable future. For more than 75 years, SRI has had a profound impact on every one of our lives through the discovery and development of groundbreaking technologies and products and by bringing many of the world's most extraordinary innovations and ideas to the marketplace. Learn more at www.sri.com.

Subtle, Inc., is a medical imaging software company. Our goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. We use the state-of-art proprietary deep learning AI algorithms to renovate the radiology workflow to deliver faster, safer and smarter solutions for imaging exams.

Supercede Therapeutics develops novel therapeutics targeting biological pathways relevant to human disease. We apply bioinformatics (AI/ML) to make drug discovery more efficient and effective.

Superfluid Dx is a biotechnology company focused on developing accurate diagnostics for neuro-degenerative diseases by harnessing the power of cell-free mRNA. They are also working on novel blood-based early detection methods.

Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company is investing in research to support the development and validation of its pipeline of prescription-based digital therapies. Swing Therapeutics' near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription-based digital therapeutic.

To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions that matter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond.

Synlico Inc. is a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program. We envision rewriting medicine by bringing causality to cellular biology. As an AI-powered drug discovery biotech company, our primary mission is to develop cutting-edge engineered T cell therapies to combat solid tumors. Harnessing advancements in single-cell bioinformatics, machine learning and causal discovery, our team is developing a computational platform that provides a granular description of the heterogeneity of the tumor microenvironment (TME) and reclassifies patients by their unique TME signatures. Our platform will enable us to design potent T cell therapies by discovering the causal relationship between intracellular elements of T cells and their behaviors in patients' TME, surmounting the challenges presented by the complex nature of solid tumors and their microenvironments.

Synthetic Design Lab is built to revolutionize antibody-drug conjugates (ADCs) with its novel SYNTHBODY™ therapeutic platform. The platform is engineered to optimize targeted payload delivery ≥10x compared to current ADCs, potentially improving upon the efficacy, safety, and overall versatility of earlier ADCs.

Tactogen is a pharmatech startup developing the next generation of MDMA-like medicines. Founded by Genentech data science leader and PhD neuroscientist Matthew Baggott and deeptech serial entrepreneur Luke Pustejovsky, Compared to existing psychedelics, our gentler, less euphoric compounds can facilitate psychotherapy, decision-making, and psychological growth while having less need for the expensive clinical monitoring. Our IP includes drug discovery methods, novel molecules, and pharmaceutical preparations. These all focus on one goal: enabling safer take-home prescription empathogens. We believe this will be the key to effective and accessible mental wellness. Tactogen: Effective Prescription Mental Wellness. For Everyone.

Terray is a biotechnology company with the technology, data, and mindset to radically change the way we discover and develop small molecule therapeutics. We explore molecules and targets broadly and deeply with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Everything the company does is grounded in an iterative approach, producing massive amounts of precise, purpose-built data that gets increasingly valuable with each cycle of design and experimentation. The company's platform uniquely blends experimentation and computation to improve the cost, speed, and success rate of small molecule drug discovery and development.

TeselaGen provides a revolutionary DNA design and assembly protocol generation service decoupling DNA design from any underlying assembly method, providing the most advanced Bio CAD/CAM system available. Taking full advantage of both in-house DNA constructs and the rapidly falling cost of de novo DNA synthesis, TeselaGen optimizes across a broad range of modern assembly techniques to produce fully scar-less DNA sequence assembly instructions ready for use at the bench or via automation. This approach releases the biologist from the major time, cost, and functionality limitations of traditional cloning to not only deliver the best overall assembly protocol, but to also create DNA constructs that may not be achievable by any other means. With TeselaGen's proprietary technology, these advances are now available for biologists at all levels of expertise who wish to assemble DNA simply, reliably, inexpensively, and with high fidelity.

ThinkCyte's mission is to provide scientists and biomedical professionals with a transformational single-cell technology that accelerates biological discoveries and enable the development of novel treatments and diagnostics through the integration of advanced hardware, machine learning, and biotechnology.

The Tierra platform allows researchers to produce a wide diversity of proteins, including ones that are difficult or impossible to produce in common types of laboratory cells.

Trace Genomics is a pioneer in the use of hi-definition genomics to activate the hidden insights in soil for healthier soils and a healthier planet. Through innovation in genomics, soil science and machine learning, Trace Genomics creates a pathway to deliver targeted database insights and actions at cost-speed-scale-accuracy for partners who are advancing modern farming solutions for a net-zero food production system. Where most companies deliver a partial picture, we provide a comprehensive and precise understanding of the soil’s composition—analyzing the soil’s biology, physical properties and chemistry. Trace Genomics has won several awards, including being selected as a 2020 Technology Pioneer by the World Economic Forum, Winner of FoodShot Global’s Innovating Soil 3.0 Challenge, Forbes Top 25 Most Innovative AgTech, THRIVE Top 50 AgTech, 2022 Global Cleantech top 100 start-ups and many more.

We are focused on drug discovery at unprecedented speed and scale, with lower risk and higher certainty across multiple diseases in parallel. With data from hundreds of millions of experiments, we have mapped the effects of thousands of compounds on gene expression to discover new therapies. Our Drug-Gene Atlas maps molecular structure and drug action to the whole cell transcriptome, revealing therapeutic candidates that rebalance gene expression to treat disease. Our proprietary artificial intelligence modeling suite, Conductor AI, used our Drug-Gene Atlas to discover and predict the effects of new drugs at transcriptome scale.

Unlearn.AI is a healthcare artificial intelligence company that specializes in medical research using machine learning techniques.

Unlocking the potential of macrocycle drug discovery through machine learning and massively parallel synthesis

An external catheter system created to improve quality of life, comfort, and self-esteem for both men and women. Rethink catheter choices at ur24technology.com

Vala Sciences helps researchers achieve an unrivaled in vitro understanding of how human cells respond to drug compounds. Vala is committed to providing expert services to pharmaceutical developers and researchers to help overcome the persistent challenge of reducing avoidable clinical failures of drug candidates in the following areas: Cardiac biology: By precisely measuring up to three channels (voltage, calcium, and contractility) of single-cell hiPSC-cardiomyocyte kinetic data in real time and comparing cell responses with known healthy or disease-model cells, Vala can help rank order drug candidates by identifying toxicities, dose response, and efficacy. Neuroscience: Vala has developed co-culture assays with hiPSC-neurons, -microglia, and -astrocytes for neurodegenerative disease drug discovery and toxicity screening. By measuring voltage and calcium kinetics, neurite and synapse formation, and engulfment by microglia, Vala can provide a detailed picture of disease mechanisms and treatment efficacy. Vala Sciences develops and manufactures the Kinetic Image Cytometer (KIC®) and Structured Illumination Microscopy (SIM) platforms, which enable information-rich measurements for making new insights into the cell biology of disease. CyteSeer®, our cell image analysis software, can resolve billions of single-cell data points from fixed or live cells. Vala’s toolset allows researchers to perform accurate, cost-effective screens for drug candidates with high probability of clinical success and low probability of side effects. We provide varied and validated high content screening services that quantify the effects of compound libraries on a number of target molecules. Vala is a registered supplier on Scientist.com. Visit our profile here: https://app.scientist.com/domain_switcher?redirect=/providers/vala-sciences

At Veebot, we are revolutionizing venipuncture through automation, medical imaging and machine precision. As you may know, venipuncture is one of the most common procedures around with 1.4B operations done a year in the US alone. It also happens to be a painful process for all involved -- from the patient that requires multiple painful attempts, to the stressed out nurse that risks a deadly needlestick injury, or the medical facility that has to pay for all the wasted time, materials, and procedures. At an estimated global market size of $1.9B annually, we believe this is a problem worth solving. We have gained initial traction through winning second place at the Stanford BASES 150k challenge, graduation from the Stanford hardware accelerator Forge, and being admitted into the StartX program. Currently, we are in the process of raising a round of financing as well as growing our board of advisers.

Velia was created to uncover the dark matter of the human proteome. Their scientific founders built the technologies to identify novel, protein coding sequences hidden within the human genome. Their pioneering work has uncovered the importance and therapeutic potential of these small proteins. To date, Velia has identified >2,500 novel “microproteins” and the list continues to grow. Early studies highlight that these small proteins mediate rich and diverse human biology.

Ventoux Biosciences is working to transform treatment for Dupuytren's and related, under-served, immuno-fibrotic diseases. Founded by a Dupuytren's patient and propelled by a team with Dupuytren's and fibrosis expertise from bench to bedside – we seek to revolutionize current treatment options via development of novel, first-line, disease-modifying, non-surgical options for patients. Dupuytren's is a chronic, progressive, debilitating and often painful fibrosis of the hands and is >3x more prevalent than Rheumatoid Arthritis. However; no cure and no approved disease slowing agents exist. Unlike RA, surgery remains as the standard of care for Dupuytren's patients. Following positive anti-fibrotic data in an established scleroderma / dermal fibrosis model, we are working to advance our lead candidate VEN-201 to human studies. Our business strategy is to expedite treatment for patients by leveraging expedited FDA clinical & regulatory pathways. Dupuytren's impacts ~265m patients across 7 major markets and upwards of 10 million patients in the U.S. alone. VEN-201 represents a potential novel, differentiated, first-line treatment to slow disease progression and help patients maintain hand function and delay potential progression to surgery or surgical interventions.

Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our growing menu of diagnostic tests answers important clinical questions to help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment.

Verana Health (formerly DigiSight) enables life science companies to make informed decisions using real-world data from itsclinical specialty database

Verily is an Alphabet company combining a data-driven, people-first approach to bring the promise of precision health to everyone, every day. We are focused on generating and applying evidence from a wide variety of sources to change the way people manage their health and the way healthcare is delivered - shifting the paradigm from “one size fits all” medicine to one focused on a more comprehensive view of the individual that leads to a more personalized path forward. For more information, please visit verily.com. Verily is hiring! Check out what's available globally at verily.com/careers.

VeriSIM Life is building AI enabled biosimulation models. VeriSIM will tackle one of the biggest obstacles of drug development: animal testing for drug development. Animal testing is slow, ethically questionable, and doesn't act as much of a filter: 92% of all drug candidates that pass this preclinical testing never make it to market. VeriSIM's solution is to create disease-specific biosimulation models, which allow researchers at pharma companies to model in software how a drug will interact in animals. This will allow researchers to test 1000x more potential candidates in the same unit of time, ensuring that drugs that do make it to (human) clinical trials are far more likely to work, and therefore saving millions in annual costs.

Viomeanalyzes your microbiome and uses artificial intelligence to process the results and provide dietary advice.

We are a team of experts driven by complex image analysis problems. ViQi is modernizing image processing technology and expediting science discovery through the creation of AI-based assay development systems. Our technology not only generates better results, but our cloud-based platform allows us to scale quickly and interact with over 150 types of large-scale image formats. Currently our technology is employed in life sciences, specifically virology and high content image analysis; digital pathology and environmental monitoring. Our cloud based solutions enable any lab access to our software and reporting. Follow us to get updates on latest discoveries, customer collaborations such as webinars or publications and more.

Vir Biotechnology, Inc. (in Europe, Humabs BioMed, https://bit.ly/46lQGN2) is an immunology company focused on powering the immune system to address unmet patient needs in infectious disease and beyond. Our powerful R&D engine combines our proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities, enabling us to engineer our rich database of human antibodies and deliver transformative medicines for diseases with significant global burden. Our current pipeline consists of multiple clinical candidates targeting hepatitis B and hepatitis delta viruses and human immunodeficiency virus, including a potential functional cure for chronic hepatitis B and treatment for chronic hepatitis delta. Our portfolio of broad, potent investigational monoclonal antibodies also targets influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus and human papillomavirus, and our investigational T cell vaccine aims to prevent HIV. Explore our full pipeline: https://bit.ly/3tr7FPm We collaborate with some of the world’s leaders in industry as well as government agencies and non-profit organizations enabling us to rapidly advance cutting-edge scientific discoveries and innovative technologies with the potential to benefit people around the world. We are proud to have been ranked the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500™. Join us as we pursue our mission to transform lives. It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN

Virgo Surgical Video Solutions provides the leading cloud video capture, management, and artificial intelligence analysis platform for endoscopic medicine. The Virgo platform is used by a range of academic, integrated, and private practice healthcare providers to advance patient care through video-based research and training initiatives. In 2021, Virgo launched a suite of tools, called VirgoTrials, which helps pharmaceutical trial sponsors and their participating trial sites accelerate patient recruitment and shorten the overall enrollment period for trials. For more information, visit https://www.virgosvs.com

VitalConnect is a leader in wearable biosensor technology. Its technology is routinely used for cardiac monitoring as well as patient monitoring in the hospital and at home. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect's products, the Vista Solution™ platform, and VitalPatch® biosensor are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions.

Vivid Genomics enables pharma companies to select and stratify the right patients for their clinical trials, increasing the probability of trial success and getting to an approved drug. We use machine learning and genomics to develop blood-based, genetic tests (“Genomic BiopsyTM”) for neurodegenerative diseases, beginning with Alzheimer’s.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai® One is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Xcell Biosciences (xcellbio) is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell's mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing. For more information, please visit http://www.xcellbio.com/.

XP Health is a digital-first vision platform focused on eye exams and eyewear that uses customer-centric design and technology to be more affordable, accessible, and provide a better member experience. XP Health was founded to combat the often confusing, expensive, and frustrating experiences common with vision insurance. The company was named to Fast Company’s list of “The World's Most Innovative Companies,” and in 2022 expanded from 30 to 1500+ customers.

Zeto has developed a wireless, portable full-montage EEG headset with dry electrodes and cloud platform. Zeto's products revolutionize EEG care by offering quick setup, residue free dry electrodes for high-quality EEGs and seizure detection, 24/7 monitoring and round-the-clock remote interpretation services. Zeto is on a mission to dramatically improve EEG access, bringing to market EEG that's so easy to use in both inpatient and outpatient settings.